Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.

Join Sangamo and be a part of our team and grow with us. We believe Sangamo has a once-in-a-lifetime opportunity to transform the future of medicine. Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.

Dec 30, 2024 · RICHMOND, Calif.--(BUSINESS WIRE)--Dec. 30, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of adults with moderately severe to severe ...

Dec 19, 2024 · Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to ...

Nov 12, 2024 · Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

View Sangamo's open positions and be a part of our team and grow with us. We believe Sangamo has a once-in-a-lifetime opportunity to transform the future of medicine.

Meet the Sangamo Therapeutics Management Team. Know our executive leadership team and board of directors here. Sangamo and Astellas Announce Capsid License Agreement to Deliver Genomic Medicine for Neurological Diseases

Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today’s medicine can only offer symptom management at best. Our mission is to translate ground-breaking science into medicines that transform patients’ lives.

Sangamo’s technology platform enables us to make genomic medicines using ex vivo cell therapy, in vivo genome engineering, and gene therapy. Click to know more.